Scribe Therapeutics, Inc. (SCTX) shareholders
Close on Nov 13, 2026Market cap $309.72MP/E –Yield –
Ownership
Who owns Scribe Therapeutics's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Aghazadeh Behzad Joint filing with Avoro Capital Advisors LLC (13.78%) | 3,088,888 | 16.37% | 13D (active) | Jul 24, 2026 |
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (9.60%), Rajeev Shah (9.60%) and 1 more | 1,802,178 | 9.60% | 13G (passive) | Jul 27, 2026 |
| ELI LILLY & Co | 1,388,161 | 7.30% | 13D (active) | Jul 23, 2026 |
| Orbimed Advisors LLC Joint filing with Orbimed Capital Gp Viii LLC (7.20%) | 1,348,825 | 7.20% | 13D (active) | Jul 27, 2026 |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SCTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| ARK Genomic Revolution ETF | 352,097 | 1.86% | $6.86M | 0.44% | Jul 31, 2026 |
| Franklin Biotechnology Discovery Fund | 135,567 | 0.72% | $2.64M | 0.23% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Benjamin L. Oakes | President, CEO, Director | 506,602 | 2.68% | Jul 27, 2026 |
| David Parrot | Chief Financial Officer | 2,666 | 0.01% | Jul 27, 2026 |
| Svetlana Lucas | Chief Business Officer | 33,695 | 0.18% | Jul 27, 2026 |
| Carl L. Gordon | Director | 348,825 | 1.84% | Jul 29, 2026 |
| Advisors Llc Orbimed | Director | 348,825 | 1.84% | Jul 29, 2026 |
| Capital GP VIII LLC OrbiMed | Director | – | – | Jul 29, 2026 |
| Behzad Aghazadeh | Director, 10% owner | – | – | Jul 28, 2026 |
| Capital Advisors LLC Avoro | Director, 10% owner | – | – | Jul 28, 2026 |
| Ventures LLC Avoro | Director | 3,088,888 | 16.32% | Jul 28, 2026 |
| Joshua Bleharski | Director | – | – | Jul 27, 2026 |
| James Dean Watson | Director | – | – | Jul 27, 2026 |
| Benjamin A. Horowitz | 10% owner | – | – | Jul 29, 2026 |
| AH Equity Partners Bio III, L.L.C. | 10% owner | – | – | Jul 29, 2026 |
| Marc L. Andreessen | 10% owner | – | – | Jul 29, 2026 |
| Jennifer A. Doudna | 10% owner | 603,547 | 3.19% | Jul 29, 2026 |
| AH Bio Fund II, L.P. | 10% owner | – | – | Jul 29, 2026 |
| AH Equity Partners Bio II, L.L.C. | 10% owner | 2,749,392 | 14.52% | Jul 29, 2026 |
| AH Bio Fund III, L.P. | 10% owner | – | – | Jul 29, 2026 |
| Brett Staahl | 10% owner | 524,336 | 2.77% | Jul 28, 2026 |
| LILLY & Co ELI | 10% owner | 1,054,828 | 5.57% | Jul 23, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ventures LLC Avoro Director | Jul 28, 2026 | Buy | +7,905 | $18.25 | $144.27K | 3,088,888 |
| AH Equity Partners Bio II, L.L.C. 10% owner | Jul 27, 2026 | Conversion | +2,051,742 | – | – | 2,051,742 |
| AH Equity Partners Bio II, L.L.C. 10% owner | Jul 27, 2026 | Conversion | +697,650 | – | – | 697,650 |
| AH Equity Partners Bio II, L.L.C. 10% owner | Jul 27, 2026 | Buy | +333,333 | $15.00 | $5.00M | 2,385,075 |
| Carl L. Gordon Director | Jul 27, 2026 | Conversion | +348,825 | – | – | 348,825 |
| Carl L. Gordon Director | Jul 27, 2026 | Buy | +1,000,000 | $15.00 | $15.00M | 1,348,825 |
| Jennifer A. Doudna 10% owner | Jul 27, 2026 | Conversion | +12,511 | – | – | 603,547 |
| Advisors Llc Orbimed Director | Jul 27, 2026 | Conversion | +348,825 | – | – | 348,825 |
| Advisors Llc Orbimed Director | Jul 27, 2026 | Buy | +1,000,000 | $15.00 | $15.00M | 1,348,825 |
| Ventures LLC Avoro Director | Jul 24, 2026 | Buy | +2,333,333 | $15.00 | $35.00M | 3,030,983 |
| Ventures LLC Avoro Director | Jul 24, 2026 | Buy | +50,000 | $22.31 | $1.12M | 3,080,983 |
| David Parrot Chief Financial Officer | Jul 23, 2026 | Buy | +1,333 | $15.00 | $20.00K | 1,333 |
| David Parrot Chief Financial Officer | Jul 23, 2026 | Buy | +1,333 | $15.00 | $20.00K | 1,333 |
| Svetlana Lucas Chief Business Officer | Jul 23, 2026 | Buy | +3,000 | $15.00 | $45.00K | 3,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 4 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Scribe Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 92,177 shares on Sep 21, 2026 over the last 90 days.
See a number that looks wrong?